Announcements
- Pharming Group to participate in June investor conferences
- Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
- Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
- Pharming Group to participate in May investor conference
- Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025
- Pharming Group reports first quarter 2024 financial results and provides business update
- Pharming Group to report first quarter 2024 financial results on May 8
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
- Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
- Pharming Group announces the placement of €100 million convertible bonds due 2029
More ▼
Key statistics
As of last trade Pharming Group NV (PHGN:FRA) traded at 0.818, 7.42% above its 52-week low of 0.7615, set on May 31, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.818 |
---|---|
High | 0.818 |
Low | 0.818 |
Bid | 0.7985 |
Offer | 0.83 |
Previous close | 0.7615 |
Average volume | 2.03k |
---|---|
Shares outstanding | 673.44m |
Free float | 657.70m |
P/E (TTM) | -- |
Market cap | 552.10m EUR |
EPS (TTM) | -0.016 EUR |
Data delayed at least 15 minutes, as of Jun 03 2024 07:16 BST.
More ▼